Company Performance - Aspira reported a quarterly loss of $0.23 per share, better than the Zacks Consensus Estimate of a loss of $0.28, and an improvement from a loss of $0.48 per share a year ago, representing an earnings surprise of 17.86% [1] - The company posted revenues of $2.26 million for the quarter ended September 2024, missing the Zacks Consensus Estimate by 13.19%, and showing a slight increase from year-ago revenues of $2.22 million [2] - Over the last four quarters, Aspira has surpassed consensus EPS estimates three times, but has only topped consensus revenue estimates once [2] Stock Outlook - Aspira shares have declined approximately 81.8% since the beginning of the year, contrasting with the S&P 500's gain of 23.6% [4] - The current consensus EPS estimate for the coming quarter is -$0.25 on revenues of $2.9 million, and -$1.26 on revenues of $10.1 million for the current fiscal year [8] - The estimate revisions trend for Aspira is mixed, resulting in a Zacks Rank 3 (Hold), indicating that shares are expected to perform in line with the market in the near future [7] Industry Context - The Medical - Instruments industry, to which Aspira belongs, is currently in the top 24% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% [9] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [6]
Aspira (AWH) Reports Q3 Loss, Lags Revenue Estimates